Progyny (PGNY) Aandelenoverzicht
Progyny, Inc., een benefits management bedrijf, biedt oplossingen voor vruchtbaarheid, gezinsvorming en vrouwengezondheidszorg in de Verenigde Staten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 5/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
Geen risico's gedetecteerd voor PGNY uit onze risicocontroles.
PGNY Community Fair Values
Create NarrativeSee what 51 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Progyny, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$27.12 |
| 52 Week Hoogtepunt | US$33.07 |
| 52 Week Laag | US$16.10 |
| Bèta | 0.99 |
| 1 maand verandering | -2.62% |
| 3 maanden verandering | 5.73% |
| 1 Jaar Verandering | 19.84% |
| 3 jaar verandering | -23.17% |
| 5 jaar verandering | -55.26% |
| Verandering sinds IPO | 70.14% |
Recent nieuws en updates
Seeking Alpha • Sep 05
Progyny: Slow But Consistent Growth With A Pristine Balance Sheet
Summary Progyny, Inc. offers fertility benefits management, growing eligible members to 7.2 million and posting steady revenue and EPS growth. PGNY reported Q2 revenues of $350.5M (+5.3% YoY) and guided FY revenue to $1.36–$1.385B, with non-GAAP EPS of $2.04–$2.10. Shares trade at just under 13x FY2026E EPS, supported by a net cash balance and $142.5M remaining on its repurchase authorization. An updated analysis around this slow-growth name with a pristine balance sheet follows in the paragraphs below. Read the full article on Seeking Alpha
Narratiefupdate • Aug 25
PGNY: Future Utilization And Renewal Trends Will Support Policy Tailwinds
Progyny's analyst fair value estimate has shifted from $26.43 to $30.00, reflecting updated models that consider a higher assumed future P/E, mixed revisions to price targets across the Street, and analyst views on the company’s growth avenues and utilization visibility. Analyst Commentary Recent Street research on Progyny offers a mixed picture for investors, with some firms more constructive on the story and others flagging execution and visibility issues.
Narratiefupdate • Aug 11
PGNY: Client Renewals And Conservative Guidance Will Drive Future Share Upside
Progyny's updated fair value estimate has moved higher to $33.82 from $29.73 as analysts raised price targets into a $33 to $40 range, citing solid recent results, broad client renewals, and ongoing confidence in the fertility benefits platform, even as some research points to moderating utilization trends and a more balanced risk and reward profile. Analyst Commentary Recent Street commentary on Progyny gives you a mixed but detailed picture of how professionals are thinking about the stock.
Narratiefupdate • Jul 28
PGNY: Fertility Utilization Trends And Guidance Are Expected To Support Upside
Progyny's updated analyst price target of $40, up from $34.92, reflects analysts' refreshed models that incorporate modestly higher revenue growth, profit margin assumptions, and a higher future P/E multiple, supported by a series of recent target increases across the Street. Analyst Commentary Bullish analysts have steadily lifted price targets on Progyny over recent months, signaling growing confidence in the company’s execution and long term growth potential.Recent updates
Seeking Alpha • Sep 05
Progyny: Slow But Consistent Growth With A Pristine Balance Sheet
Summary Progyny, Inc. offers fertility benefits management, growing eligible members to 7.2 million and posting steady revenue and EPS growth. PGNY reported Q2 revenues of $350.5M (+5.3% YoY) and guided FY revenue to $1.36–$1.385B, with non-GAAP EPS of $2.04–$2.10. Shares trade at just under 13x FY2026E EPS, supported by a net cash balance and $142.5M remaining on its repurchase authorization. An updated analysis around this slow-growth name with a pristine balance sheet follows in the paragraphs below. Read the full article on Seeking AlphaNarratiefupdate • Aug 25
PGNY: Future Utilization And Renewal Trends Will Support Policy Tailwinds
Progyny's analyst fair value estimate has shifted from $26.43 to $30.00, reflecting updated models that consider a higher assumed future P/E, mixed revisions to price targets across the Street, and analyst views on the company’s growth avenues and utilization visibility. Analyst Commentary Recent Street research on Progyny offers a mixed picture for investors, with some firms more constructive on the story and others flagging execution and visibility issues.Narratiefupdate • Aug 11
PGNY: Client Renewals And Conservative Guidance Will Drive Future Share Upside
Progyny's updated fair value estimate has moved higher to $33.82 from $29.73 as analysts raised price targets into a $33 to $40 range, citing solid recent results, broad client renewals, and ongoing confidence in the fertility benefits platform, even as some research points to moderating utilization trends and a more balanced risk and reward profile. Analyst Commentary Recent Street commentary on Progyny gives you a mixed but detailed picture of how professionals are thinking about the stock.Narratiefupdate • Jul 28
PGNY: Fertility Utilization Trends And Guidance Are Expected To Support Upside
Progyny's updated analyst price target of $40, up from $34.92, reflects analysts' refreshed models that incorporate modestly higher revenue growth, profit margin assumptions, and a higher future P/E multiple, supported by a series of recent target increases across the Street. Analyst Commentary Bullish analysts have steadily lifted price targets on Progyny over recent months, signaling growing confidence in the company’s execution and long term growth potential.Narratiefupdate • Jul 14
PGNY: Measured Fair Value View As Fertility Utilization And Guidance Shape Outlook
Analysts have lifted the fair value estimate for Progyny to $34.92 from $33.00, reflecting updated views on revenue growth, profitability, and future P/E assumptions, alongside a series of recent price target increases across the Street. Analyst Commentary Recent research updates on Progyny point to a cluster of higher price targets and an upgrade, with several bullish analysts highlighting company execution, utilization trends, and the positioning of its fertility benefits platform.Narratiefupdate • Jun 16
PGNY: Conservative Guidance And Share Repurchases Will Support Future Stock Upside
Analysts have trimmed the fair value estimate for Progyny to $29.73 from $30.91, as updated assumptions around growth, profitability, and future P/E multiples reset the stock's risk and return profile, even as Street price targets have moved higher into the $27 to $31 range. Analyst Commentary Street research around Progyny stock has tilted constructive, with several firms lifting price targets into the high US$20s and low US$30s.Narratiefupdate • Jun 01
PGNY: Healthy Utilization And Client Transition Progress Will Support Future Policy Tailwinds
Progyny's analyst price target has been revised slightly higher to $26.43. Analysts point to the company's conservative guidance track record, better than expected recent utilization trends, and expectations that difficult comparisons related to a large client transition could ease over time.Analyse-artikel • May 16
The Strong Earnings Posted By Progyny (NASDAQ:PGNY) Are A Good Indication Of The Strength Of The Business
Progyny, Inc. ( NASDAQ:PGNY ) recently posted some strong earnings, and the market responded positively. Our analysis...Narratiefupdate • Mar 09
PGNY: Healthy Utilization And Member Engagement Will Support Future Policy Tailwinds
Analysts have trimmed their average price targets for Progyny to a range of about $28 to $30 from $32 to $35, reflecting slightly lower growth assumptions and a more conservative P/E. The revised targets still point to solid underlying member engagement and demand outside specific client transitions.Narratiefupdate • Feb 23
PGNY: Resilient Employer Demand And Conservative Guidance Will Support Future Upside
Narrative Update on Progyny Analysts have raised their average price target on Progyny to $34 from $30, supported by views that demand remains resilient beyond key clients, that concerns around ProgynyRx are better understood as a coverage mismatch, and that the company’s conservative guidance approach offers clearer visibility with fewer expected surprises. Analyst Commentary Recent Street research on Progyny clusters around a more constructive view of the business, with price targets lifted into the low to mid US$30s and several ratings moving higher.Narratiefupdate • Feb 08
PGNY: Emerging Employer Demand And Catalysts Will Support Future Upside Potential
Narrative Update on Progyny The analyst price target for Progyny has moved higher by about US$1.50 per share. Analysts point to increased targets at several firms, resilient demand outside key accounts, emerging catalysts, and updated P/E and margin assumptions as key supports for their revised views.Narratiefupdate • Jan 24
PGNY: Policy Tailwinds And Utilization Trends Will Balance Competition And Regulatory Risks
Analysts have nudged their price targets on Progyny higher, including recent US$2 to US$6 increases from several firms, pointing to resilient demand, a conservative guidance style that reduces surprise risk, and what they view as emerging catalysts that help offset concerns around competition, regulation, and ProgynyRx utilization. Analyst Commentary Recent research commentary on Progyny has leaned constructive on the story, with several firms lifting ratings or price targets and pointing to what they see as resilient demand, conservative guidance, and potential catalysts.Narratiefupdate • Jan 10
PGNY: Policy Tailwinds And Utilization Trends Will Shape Fertility Benefits Demand
Analysts have raised their fair value estimate for Progyny to $26 from $21, citing expectations for stronger revenue growth and profit margins, a higher future P/E assumption, and growing confidence in demand, utilization, and policy tailwinds, as reflected in recent upgrades and price target increases from multiple research firms. Analyst Commentary Recent Street research on Progyny highlights a generally constructive stance, with multiple firms assigning Buy or Overweight ratings and setting price targets in the US$30s.Narratiefupdate • Dec 25
PGNY Emerging IVF Policy Tailwinds Will Support Stronger Long-Term Share Performance
Analysts have nudged their fair value estimate for Progyny higher to $33 from $32, citing emerging utilization and policy tailwinds that support slightly faster revenue growth and improving profit margins despite a modestly higher discount rate and lower future P E multiple. Analyst Commentary Bullish analysts highlight that recent upgrades and rising price targets reinforce confidence in Progyny's ability to deliver above consensus growth, with improving utilization trends and policy tailwinds supporting a higher fair value range in the low to mid 30s.Narratiefupdate • Dec 11
PGNY Emerging IVF Coverage Tailwinds Will Drive Upside Potential
Analysts have modestly raised their fair value estimate for Progyny from $28.25 to $29.40 per share, citing emerging positive catalysts, stronger expected utilization on higher eligible lives, and potential incremental tailwinds from expanding IVF awareness and coverage. Analyst Commentary Bullish analysts see the recent upgrade and price target moves as validation that Progyny's fundamentals and growth prospects are underappreciated at current levels, with the stock offering an attractive risk reward skew.Narratiefupdate • Sep 05
Rising Demand For Women's Health Will Transform Market Opportunity
Analysts cite improving membership trends, positive pre-announcements, and strategic partnerships expanding Progyny's women's health services as driving renewed confidence and modest upgrades, though the consensus price target remains unchanged at $28.25. Analyst Commentary Bullish analysts cite a rebound in membership activity, highlighted by two consecutive positive pre-announcements, as signaling recovery from last year's lows and renewed momentum.Analyse-artikel • Aug 02
At US$22.49, Is It Time To Put Progyny, Inc. (NASDAQ:PGNY) On Your Watch List?
While Progyny, Inc. ( NASDAQ:PGNY ) might not have the largest market cap around , it saw significant share price...Analyse-artikel • Jul 13
Progyny (NASDAQ:PGNY) Might Have The Makings Of A Multi-Bagger
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Analyse-artikel • May 16
Progyny, Inc.'s (NASDAQ:PGNY) CEO Will Probably Struggle To See A Pay Rise This Year
Key Insights Progyny to hold its Annual General Meeting on 22nd of May Total pay for CEO Pete Anevski includes...Analyse-artikel • May 13
The Price Is Right For Progyny, Inc. (NASDAQ:PGNY)
Progyny, Inc.'s ( NASDAQ:PGNY ) price-to-earnings (or "P/E") ratio of 35.9x might make it look like a strong sell right...Analyse-artikel • Apr 25
At US$22.90, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?
Progyny, Inc. ( NASDAQ:PGNY ), is not the largest company out there, but it saw a decent share price growth of 16% on...Analyse-artikel • Mar 02
Progyny, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Progyny, Inc. ( NASDAQ:PGNY ) shareholders are probably feeling a little disappointed, since its shares fell 2.9% to...Seeking Alpha • Feb 06
The Play On Progyny: Don't Chase, But Watch And Wait
Summary Progyny, Inc. shares have fallen substantially from their 2024 peak due to disappointing FY24 outlooks and increased competition, including the loss of its largest client. Despite strong historical growth and a 99% renewal rate, fewer initial fertility consultations are leading to assisted reproductive treatments, challenging revenue predictability. PGNY stock has rebounded nicely over the past few weeks, and the shares saw some insider buying late in December. An analysis around Progyny follows in the paragraphs below. Read the full article on Seeking AlphaAnalyse-artikel • Jan 30
Capital Allocation Trends At Progyny (NASDAQ:PGNY) Aren't Ideal
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Seeking Alpha • Jan 15
Progyny: The Growth Story Remains Intact
Summary Progyny, Inc.'s stock is undervalued due to overreaction to bad news; the company remains fundamentally strong with solid customer growth and free cash flow generation. Despite losing Amazon as a client, Progyny's retention rate is 99%, and the company is well-positioned to benefit from long-term secular tailwinds in fertility benefits. Progyny's proprietary “Smart Cycle” plan and strong partnerships with Fortune 500 companies highlight its competitive advantage and growth potential in the fertility benefits market. With a strong balance sheet, recent insider buys, and a strategic focus on international expansion, Progyny represents a good risk/reward play at current prices. Read the full article on Seeking AlphaAnalyse-artikel • Jan 12
Progyny, Inc.'s (NASDAQ:PGNY) P/E Is Still On The Mark Following 28% Share Price Bounce
Progyny, Inc. ( NASDAQ:PGNY ) shareholders would be excited to see that the share price has had a great month, posting...Analyse-artikel • Jan 03
Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?
Progyny, Inc. ( NASDAQ:PGNY ), is not the largest company out there, but it led the NASDAQGS gainers with a relatively...Seeking Alpha • Dec 31
The Bottom Fishing Club: Progyny Reverses On Heavy Insider Buying
Summary Progyny shares have plummeted nearly 80% from 2021's peak, but management optimism and insider buying in December signal a potential turnaround during 2025. PGNY's valuation is deeply discounted, with strong fundamentals: $235M in cash, no debt, and 9.64% in trailing free cash flow yield. The stock's rare accumulation/momentum pattern since September and potential short squeeze kicker make it an attractive Buy. Read the full article on Seeking AlphaSeeking Alpha • Nov 26
Progyny: Rating Downgrade On Uncertain Growth Outlook
Summary I recommend downgrading Progyny from buy to hold due to a loss of confidence in its growth outlook and increased uncertainty. PGNY's Q3 2024 results were disappointing, with revenue and margins falling short of expectations, leading to lowered FY24 guidance. Declines in ART cycles and a weaker 2024 sales season raise concerns about underlying demand, despite potential upsides from upselling adjacent solutions. Valuation multiples are unlikely to improve given the poor growth outlook, making it difficult to justify a bullish stance on PGNY. Read the full article on Seeking AlphaAnalyse-artikel • Nov 21
Progyny's (NASDAQ:PGNY) Solid Earnings Have Been Accounted For Conservatively
The market seemed underwhelmed by the solid earnings posted by Progyny, Inc. ( NASDAQ:PGNY ) recently. Our analysis...Seeking Alpha • Nov 18
Progyny: After A Terrible Year, I'm Out (Rating Downgrade)
Summary I initially rated Progyny a "Buy" in late 2022, but 2024 has been disastrous, with a 60% stock drop and loss of Amazon as a client. Q3 2024 financials show minimal revenue growth, declining margins, and lower earnings per share, despite a strong balance sheet. Given management's struggles and increased competition, I no longer believe Progyny has a competitive advantage and have sold my shares. Read the full article on Seeking AlphaAnalyse-artikel • Oct 21
Here's What's Concerning About Progyny's (NASDAQ:PGNY) Returns On Capital
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Seeking Alpha • Oct 15
Progyny: Poor Year Raises Concerns For Future (Downgrade)
Summary Progyny has had a rough start to the year, with the share price declining by double digits in response to both Q1'24 and Q2'24. In September, they filed an 8-K informing investors that they lost their largest client, accounting for 13% of revenue. Shares declined 30% as a result. This article reviews the year for PGNY so far, outlines why I am reluctant to pick up more shares at these depressed prices, and why the fertility space remains interesting. Read the full article on Seeking AlphaAnalyse-artikel • Sep 29
Progyny, Inc.'s (NASDAQ:PGNY) Stock Retreats 28% But Earnings Haven't Escaped The Attention Of Investors
To the annoyance of some shareholders, Progyny, Inc. ( NASDAQ:PGNY ) shares are down a considerable 28% in the last...
Nieuw narratief • Sep 11
Expanding Market Reach And Enhancing Services Spur Optimistic Revenue And Profit Forecasts
Anticipated decrease in ART cycle utilizations may negatively affect revenue due to lower fertility treatment rates.Seeking Alpha • Aug 15
Progyny: Downgrading As Uncertainties Increase
Summary Progyny lowered full-year revenue guidance after seeing an unexpected drop in user utilization rates. The Harris-Walz ticket has put fertility benefits center stage in the upcoming presidential election, which makes the stock more volatile in the short term. Despite current challenges, Progyny's long-term growth thesis remains intact, with potential opportunities for expansion in the future. Read the full article on Seeking AlphaRendement voor aandeelhouders
| PGNY | US Healthcare | US Markt | |
|---|---|---|---|
| 7D | 3.2% | -1.6% | -0.2% |
| 1Y | 19.8% | 18.2% | 14.8% |
Rendement versus industrie: PGNY overtrof de US Healthcare industrie, die het afgelopen jaar een rendement 18.2 % opleverde.
Rendement versus markt: PGNY overtrof de US markt, die het afgelopen jaar een rendement opleverde van 14.8 %.
Prijsvolatiliteit
| PGNY volatility | |
|---|---|
| PGNY Average Weekly Movement | 4.9% |
| Healthcare Industry Average Movement | 7.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: PGNY heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van PGNY is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2008 | 846 | Pete Anevski | www.progyny.com |
Progyny, Inc., een benefits management bedrijf, biedt oplossingen op het gebied van vruchtbaarheid, gezinsvorming en vrouwengezondheidszorg in de Verenigde Staten. Het biedt oplossingen voor vruchtbaarheidsuitkeringen, zoals een gedifferentieerd plan met slimme behandelingsbundel, persoonlijke ondersteuningsdiensten voor leden in conciërge-stijl en een selectief netwerk van vruchtbaarheidsspecialisten. Het bedrijf biedt ook Progyny Rx, een geïntegreerde oplossing voor apotheekvoordelen die toegang biedt tot de medicijnen die nodig zijn tijdens de behandeling en care management services biedt, evenals oplossingen voor zwangerschap en postpartum, menopauze en midlife, uitkerings- en verlofnavigatie en welzijn voor ouders en kinderen.
Progyny, Inc. Samenvatting
| PGNY fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$2.08b |
| Inkomsten(TTM) | US$78.63m |
| Inkomsten(TTM) | US$1.31b |
26.5x
Koers/Winstverhouding1.6x
P/S-verhoudingIs PGNY overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| PGNY resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$1.31b |
| Kosten van inkomsten | US$988.68m |
| Brutowinst | US$322.09m |
| Overige uitgaven | US$243.46m |
| Inkomsten | US$78.63m |
Laatst gerapporteerde inkomsten
Jun 30, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 1.02 |
| Brutomarge | 24.57% |
| Nettowinstmarge | 6.00% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde PGNY op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/09 16:46 |
| Aandelenkoers aan het einde van de dag | 2026/09/09 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Progyny, Inc. wordt gevolgd door 21 analisten. 11 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Peter Warendorf | Barclays |
| Zhilin Long | Berenberg |
| Nisala Weerasuriya | Berenberg |